Release Date: 23-Jan-2025
IBI322 is a promising bispecific antibody developed by Innovent Biologics, designed to target two key immunosuppressive pathways that tumors exploit to evade the immune system. It is a recombinant anti-human CD47/PD-L1 antibody that aims to enhance both innate and adaptive immune responses to fight cancer. As a bispecific antibody, IBI322 simultaneously targets CD47, a "don't eat me" signal on tumor cells, and PD-L1, an immune checkpoint ligand that suppresses T cell activation. By blocking the CD47/SIRPandalpha; pathway and the PD-1/PD-L1 pathway, IBI322 has the potential to activate both macrophages and T cells, thereby promoting immune-mediated destruction of tumor cells.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
One of the key advantages of IBI322 lies in its design, which provides a more selective and potentially safer approach to cancer treatment. It features an "imbalanced" binding affinity: a lower affinity for CD47 and a higher affinity for PD-L1. This design allows IBI322 to preferentially target tumor cells that express both CD47 and PD-L1, minimizing the risk of off-target effects, such as the destruction of healthy red blood cells (RBCs), which is a common issue with other CD47-targeted therapies. By reducing the impact on healthy cells, IBI322 may offer a more favorable safety profile while still providing potent anti-tumor activity.
The dual action of IBI322andmdash;activating both macrophages through CD47 blockade and T cells through PD-L1 blockadeandmdash;provides a synergistic immune response. This comprehensive approach is particularly effective in combating the immune evasion mechanisms employed by tumors. Preclinical studies have shown that IBI322 performs well in selectively targeting CD47+/PD-L1+ tumors, enhancing the activation of the immune system without significant toxicity. IBI322 is currently undergoing Phase 2 clinical trials for both hematological malignancies and solid tumors, where its ability to induce anti-tumor immunity and minimize adverse effects is being further explored. If successful, IBI322 could represent a significant advancement in cancer immunotherapy, offering a more effective and safer treatment option for a variety of cancers.